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Background & Aims: Although most drug-induced liver injury (DILI) cases resolve after the culprit
medication is discontinued, time to recovery varies among patients with 6-12% developing a chronic
disease. Here, we investigated clinical factors and drug properties as potential risk factors that influence
DILI recovery time course and developed a model to predict cases at high risk for prolonged recovery.
Methods: We applied an accelerated failure time model to 294 cases collected by the International
Drug-Induced Liver Network Consortium. Factors included in the multivariate recovery score model
were selected through univariate analysis. The model was externally validated by 385 cases from the
Spanish DILI registry and 191 cases from the LiverTox database.
Results: Higher serum bilirubin and ALP at DILI onset, a longer time to onset, and non-significant drug
metabolism were associated with a longer recovery and were included in the multivariate recovery
score model. We divided cases into risk groups based on the score assigned by the recovery score
model. The estimated probability of recovery at six months was 0.46 (95% CI:0.26-0.61) for the high-risk
group and 0.93 (95% CI:0.58-0.99) for the low-risk group. In both validation sets, the high-, and low-risk
cases identified by the model showed a significantly different time-course for recovery, with a majority
of low-risk cases recovering sooner.
Conclusion: Biochemical recovery from DILI is influenced by the extent of culprit drug metabolism and
serum bilirubin and alkaline phosphatase at DILI onset. Understanding the factors that delay DILI
recovery may give important insight into the mechanisms and development of chronic DILI and guide
patient management after DILI events.
Lay summary: In this study, we investigated whether drug properties and clinical factors affect the time
it takes to recover from drug-induced liver injury. We found that total bilirubin, ALP level at DILI onset,
time to onset, and extent of drug metabolism were consistently associated with recovery time. Using
these factors, we built a model to identify patients at a higher risk of delayed recovery and tested this
model in two independent cohorts. Our findings will give important insight into factors contributing to
delayed recovery from drug-induced liver injury.
Keywords: Drug-induced liver injury, prolonged recovery, scoring model, risk factor, accelerated failure time
Drug-induced liver injury (DILI) is a clinically significant adverse reaction. Although most DILI resolves
after discontinuation of the culprit medication, the time to recovery varies among patients with 6-12%
cases eventually developing chronic liver injury.[1, 2]
Chronic liver injury may result in fibrosis, bile duct loss, and cirrhosis and negatively impact quality of
life.[1-4] Currently, the understanding of underlying mechanisms driving the development of chronic or
persistent DILI is limited. Certain clinical factors have been reported as risk factors for chronic DILI, but
the results are not entirely consistent. For example, Fontana et al.[1] reported that cholestatic pattern
of DILI was more frequent in persistent DILI cases while Medina-Caliz et al.[3] did not find a significant
association between chronicity and cholestatic pattern. Age is another clinical factor that was significant
in some studies but insignificant in others.[1, 3, 5] A prospective study conducted by the US Drug-
Induced Liver Injury Network described 17% of the DILI cases as chronic based on abnormal serum
biochemistries six months after enrollment[5, 6] and Medina-Caliz et al. of the Spanish DILI registry
found that 8% of DILI cases persisted for more than one year.[3]
One reason for the inconsistency between studies may stem from the different definitions of chronic
DILI. Chronic cases are defined by abnormal serum chemistry values for an extended period of time,
either six months [5, 6] or one year.[3, 7] Although these studies each categorized cases as chronic
based on biological or medical rationales, the number of days of abnormal serum chemistry values is a
continuous variable and these different cut-offs could lead to inconsistent observations.
In this study, we focused on the time to recovery after DILI injury and used an accelerated failure time
model to explore host factors and drug properties and identify the potential risk factors that could
influence the time-course of DILI recovery after discontinuation of the culprit medications. We further
defined a model and score based on these factors (i.e. bilirubin and alkaline phosphatase (ALP) at DILI
onset, time to onset, extent of drug metabolism) and validated the model using two independent
ccohorts with 385 cases from the Spanish DILI registry[8] and 191 DILI cases collected from the National
Institutes of Health (NIH) LiverTox database.[9]
Materials and Methods
DILI Cohort
Cases in this study were part of the International DILI Consortium (iDILIC), a large collaborative study
with recruitment centers across Europe, Asian, and Australia. The 720 cases included in this study are
from batches 1 and 2 of the fourth release of iDILIC. Batch 3 from the fourth release was excluded
because follow-up serum biochemistries were not reported.
Inclusion criteria for cases in the iDILIC cohort were based on clinical chemistry criteria for DILI as
defined by Aithal et al.,[7] which states that a qualified case must have either alanine aminotransferase
(ALT) elevated at least five-fold above the upper level of normal (ULN), or at least a two-fold elevation of
ALP above ULN or elevated levels of ALT at least three-fold above ULN while bilirubin concentrations are
also over two-fold ULN. Cases were also assessed using the Roussel Uclaf Causality Assessment Method
(RUCAM) scoring system and expert review consisting of a panel of three hepatologists.
In this study, only cases with a RUCAM causality scale of probable (i.e. score of greater than or equal to
6) were included. In addition, only patients with initial and follow-up serum biochemistries and without
long intervals (more than six months) between the final elevated and the normalized serum
biochemistry dates were included. We excluded cases where pre-existing liver disease were present and
cases that resulted in liver transplant or death. Only causal drug combinations that occurred more than
five times in the iDILIC cohort were included. For example, amoxicillin-clavulanate and
sulfamethoxazole-trimethoprim are frequently given in combination. However, causal drug
combinations such as diclofenac and flucloxacillin, which are not frequently given in combination and
occurred less than five times in the cohort, were excluded. To avoid conflict with the validation cohort,
we excluded cases that were collected by the Spanish DILI group. The final analysis includes 294 cases.
Figure 1 describes criteria for case inclusion and exclusions.
Patient Recovery
Patient recovery was defined as whether the patient’s serum biochemistries returned to normal. Time
to recovery, or time followed, was calculated in days from the day of withdrawal of the culprit
medication[10, 11] to the date when liver serum biochemistries normalized (1xULN) or the last day of
follow-up. Patients with serum ALT, AST, ALP, or bilirubin that did not return to 1xULN were censored
at the date of their last recorded follow-up. Both censored cases and cases that returned to 1xULN
are included in the regression modeling of the accelerated failure time analysis, which is a
parametric time-to-event analysis.
Host Factors
Host factors were collected from the clinical data provided by iDILIC. Clinical information includes
medical history information, concomitant medications, liver enzymes, and other clinical features (Table
1). The type of liver injury was categorized as hepatocellular, mixed, or cholestatic using the R value at
DILI diagnosis as described by Benichou et al.[12] We defined DILI onset as the date of DILI diagnosis and
the time to DILI onset as the days from the initial drug intake to the DILI diagnosis. Liver biochemistry
tests that were taken at DILI diagnosis were included as well. Delayed drug discontinuation was defined
as the number of days from DILI diagnosis to drug discontinuation. DILI severity was categorized as
defined by Aithal et al.[7] where mild cases meet aforementioned clinical biochemistry criteria for DILI,
moderate cases meet criteria for DILI and bilirubin values are greater than two times ULN, and severe
cases meet moderate criteria and have one of the following: ascites, encephalopathy, international
normalization ratio >1.5 and/or other organ failure due to DILI.
Drug Properties
In this study, we included the following drug properties: daily dose, lipophilicity, and extent of
metabolism. Information on drug property was retrieved from the Liver Toxicity Knowledge Base[13]
and literature sources. Extent of drug metabolism is defined as high when ≥ 50%; otherwise, it is defined 
as low following the definition in Lammert et al.[14] Drug combinations that occurred more than five
times were included and their drug properties combined by taking the maximum value. Drug
combinations occurring in five or fewer cases were removed from the analysis. Causal drugs and their
frequencies are shown in Supplemental Table 1.
LiverTox Case Reports
We downloaded 389 case reports from the NIH LiverTox web site (www.livertox.nih.gov)[9] for an
independent validation analysis. The case reports include liver biochemistries, DILI severity, pattern of
injury, time to onset, age, sex, causal drug, and recovery time. After removing cases in which dietary
supplements were culprit and cases that were missing initial serum biochemistries, 191 cases remained
with a median follow-up time of 60 days (range: 4-300 days). Supplemental Table 2 includes LiverTox
drug frequencies.
Spanish DILI Registry Cases
To further validate the model, we applied the recovery score prediction to 385 cases collected by the
Spanish DILI registry.[8] These cases have a median follow-up time of 111 days (range: 5-3020 days). The
inclusion criteria used in the main iDILIC cohort were applied to this cohort as well.
Statistical Methods
Univariate Analysis
Accelerated failure time (AFT) models were used for time-toevent analysis, where the event was DILI
recovery as defined by the return of ALT, ALP, and bilirubin to normal values or 1xULN. In order to
identify clinical factors and drug properties affecting patient recovery, we first screened clinically-
relevant variables in a univariate analysis. These potential clinical risk factors included sex, age, time
to onset, and liver biochemistries (bilirubin, ALP, and ALT) at DILI onset. We also included drug
properties: daily dose, extent of metabolism, and lipophilicity. We transformed time to onset and the
liver serum biochemistry values (ALT, ALP, and bilirubin) to their natural logarithms.
Two drugs, namely amoxicillin-clavulanate and flucloxacillin, account for 28% (N=82) and 27% (N=79)
of the total cases in this cohort (N=294), respectively. Therefore, we conducted the univariate
analysis in the entire cohort as well as in subsets including only amoxicillin-clavulanate or
flucloxacillin.
Development of DILI Recovery Time Model
We then built a multivariate AFT model using factors approaching significance (p-value < 0.1) in the
univariate analysis of the entire cohort. A factor will not be selected if its correlation with other
factors is 0.3 or greater or is significantly associated with other factors (p-value <0.01). The model
was used to calculate the recovery score and divide cases into high-, indeterminate-, and low-risk
groups. Cases with a score of one standard deviation above the mean or greater were classified as
high-risk of delayed recovery, those within one standard deviation of the mean were classified as
indeterminate-risk, and those with a score one standard deviation below the mean or lower were
classified as low-risk.
To determine which AFT distribution best fit the data, we compared the models estimated under
three alternative distributional assumptions: the log-normal, Weibull, and log-logistic. All models
retain the same other assumptions, e.g. independence across patients. The models were compared
and evaluated by minimization of the Akaike information criterion (AIC) (Supplemental Table 3),
range in size of standardized residuals (Supplemental Figure 1), graphical comparison of
nonparametric modified Kaplan-Meier estimates that adjusts for covariates estimates against fitted
survival estimates (Supplemental Figure 2), and Kaplan-Meier estimates of residuals (Supplemental
Figure 3). The log-normal model had the smallest AIC, the smallest range of standardized residuals,
and also fit the Kaplan-Meier estimates based on the comparison graphs. In addition, the overall fit
of the log-normal model was also confirmed by the quantile-quantile plot of the log of time to
recovery against the theoretical normal quantiles (Supplemental Figure 4). Therefore, we selected the
log-normal distribution for the AFT multivariate model with covariates adjusted. The overall
goodness-of-fit of the AFT model was evaluated with an overlay of Cox–Snell residuals by follow-up
time, in which a straight line suggests a good model fit (Supplemental Figure 5).
The defined multivariate score model was validated by predicting prolonged recovery cases in two
independent validation cohorts consisting of 385 cases from the Spanish DILI registry and 191 cases
from the NIH LiverTox database. The risk score cut-offs defined in the original study population were
used to categorize these cases into high-, indeterminate-, and low-risk groups. Recovery rates were
determined using the Kaplan-Meier method and the log-rank test was used to compare the recovery
time between the high- and low-risk groups. We also considered performance in specific subgroups
based on injury type, case severity, and RUCAM scores.
Other Statistical Analysis
Descriptive statistics, mean and standard deviation, were used to describe continuous variables, and
frequency and percent were used to describe categorical variables. All analysis were performed using R
(version 3.6.1)[15] and the survival[16] package for the accelerated failure time model,
htmlTable[17] for clinical and drug tables, car[18] for Q-Q plots, and survminer[19] for Kaplan-Meier
plots. Code for Kaplan-Meier estimator of residuals (Supplemental Figure 3) was adapted from
Rizopoulos.[20]
Results
Clinical Characteristics of the Study Population
After applying inclusion and exclusion criteria (Figure 1), 294 cases remained. Of these, 140 cases
recovered within the follow-up period and 154 either did not recover or were lost to follow-up. The
mean/median follow-up time was 82/68 days (range: 1-587 days). The average age was 59 years (range:
14-91 years) and 60% of the cases were female. A majority of patients (94.2%) were Caucasian, 3.4%
were Asian, and the remaining 2.4% were other or unknown race. The pattern of liver injury was
cholestatic in 26% of cases, hepatocellular in 35%, and mixed in 39%. Amongst cases that recovered, the
mean/median time to biochemical recovery was 79/73 days (range: 10-259 days). In censored cases that
were lost to follow up before they fully recovered, the mean/median follow-up time was 84/59 days
(range: 1-587 days). Clinical characteristics and comorbidities of the 294 cases are shown in Table 1.
Antibiotics were responsible for 68.4% of cases, followed by NSAIDs (6.5%), and antihyperlipidemics
(3.4%). Amoxicillin-clavulanate and flucloxacillin were two of the most frequent drugs and were causal in
82 (27.9%) and 79 (26.9%) cases, respectively. Additional drug frequencies are shown in Supplemental
Table 1.
Univariate Analysis
The results for the AFT univariate are shown in Table 2. In the entire cohort, a one-unit increase in loge
of bilirubin times the upper limit of normal at DILI onset was associated with a 46% (p<0.001) and ALP a
50% longer recovery time (p<0.001). Moderate to severe clinical severity (vs. mild) was associated with a
109% longer recovery time and was statistically significant (p<0.001). Hepatocellular injury was
associated with 54% shorter recovery time compared with cholestatic injury (p<0.001). A higher bilirubin
was also associated with a prolonged recovery in the amoxicillin-clavulanate and the flucloxacillin
subgroups. A longer time to DILI onset was associated with prolonged recovery time in the amoxicillin-
clavulanate subgroup. ALT at DILI onset, age, and sex were not significant in any of the subgroups. We
also considered injury types classified by nR,[21] however; a large portion of cases (60%) lack AST values,
and ALT alone was used for classification of these cases.The results were similar with only three mixed
injury reclassified into hepatocellular injury by using nR.
Drug properties were tested in the entire cohort. Culprit drugs that are eliminated primarily through
hepatic metabolism were significantly associated with 52% shorter recovery time (Table 2), compared
with culprit drugs without significant hepatic metabolism.
DILI Recovery Time Model
Total bilirubin, ALP at DILI onset, time to onset, and extent of drug metabolism were selected for the
multivariate analysis (see Table 3), which we used to calculate recovery score. Severity and injury type
were not selected since they were derived from and correlated with other selected variables. A score
model for DILI recovery derived from the AFT log-normal approach was defined as below:
Recovery Score = 0.227 * loge(ALP xULN at onset) + 0.277 * loge(Bilirubin xULN at onset) +
0.161 * loge(time to onset) - 0.440 * (significant hepatic metabolism of culprit drug).
The range of possible recovery scores was -0.60 to 2.03, where the higher score indicates a greater
likelihood of prolonged recovery.
The cases were categorized into high-risk for prolonged recovery (recovery score > 1.30), and low-
risk (recovery score ≤ 0.44) to evaluate association between the calculated scores and the likelihood 
of delayed recovery. Cases between the threshold were indeterminate. As shown in Figure 2, the risk
groups had a significantly different time-course for recovery (p<0.0001). Specifically, the probability of
recovery at 6 months for the high-risk group was estimated as 46% (95% CI:0.26-0.61) and the low group
was 93% (95% CI:0.58-0.99). The estimated probability of recovery at three, six, and nine months was
consistently higher in the low-risk group, as shown in Table 4.
As seen in Supplemental Figure 6, cases with a RUCAM score of eight or more were categorized by the
recovery risk score model into significantly different recovery groups according to the log-rank test
(p<0.0001) but those with a score of six or seven had a higher p-value(p=0.025). This suggests that the
model performs better when applied to higher quality data.
Model validation
We then validated the model by predicting delayed recovery cases in 385 cases from the Spanish DILI
registry. The high-and low-risk cases identified by the model showed a significantly different time-course
for recovery (Figure 3, p=0.0028).
We also validated the model in 191 cases downloaded from LiverTox and applied the recovery score
model to the LiverTox cases, categorizing them into risk groups. The difference in recovery between
the high- and low-risk groups was statistically significant using a log rank test (Figure 4, p=0.0004).
The population characteristics of LiverTox cases are shown in Supplemental Table 5.
Discussion
Herein, we modeled recovery after DILI injury using clinical factors and drug properties by using an
accelerated failure time model in a large cohort of well characterized acute DILI patients. We found that
not only total bilirubin, ALP at DILI onset, time to onset but, importantly, extent of drug metabolism
were consistently associated with DILI recovery time, and a scoring model based on these factors was
developed from 294 DILI cases and validated in an independent cohort of 385 samples from the Spanish
DILI registry[8] and 191 DILI cases collected from the LiverTox database.[9] To our knowledge, this is the
first report to use regression survival analysis to investigate DILI resolution, including not just host
factors but also drug properties.
Our study has a number of strengths, including the substantial size of the cohort, multinational source,
strict inclusion criteria, and external validations of the model. The 294 well-defined DILI cases verified by
expert review and causality assessment were retrieved from the iDILIC, which is part of the International
Serious Adverse Event Consortium[22] and recruits patients primarily from DILI centers across Europe
with clinical and culprit medication information. In our study, only cases with a RUCAM score of six or
higher were included and cases with pre-existing conditions were also removed. The recovery score
model performed better when applied to cases with a RUCAM of eight or more, which suggests that the
model performs well in the higher quality cases (Supplemental Figure 6). We further considered
performance in specific subgroups including injury types and severity. We found that the model
performed best for hepatocellular cases, separating them into distinct groups (Supplemental Figure 7A,
log-rank p=0.0084). Similarly results were found in the Spanish and LiverTox validation sets. In addition,
the model performed better for moderate-severe DILI cases than mild DILI cases (Supplemental Figure
8).
Compared with the LiverTox and Spanish DILI cohorts,[3, 5] the cohort in this study has similar
demographic distribution in sex and slightly older in age, i.e. the average age at DILI diagnosis is 59 years
in this cohort, 52 years in the Spainish cohort and 49 years in the LiverTox cohort.[3, 5] Note, the cohort
here contains 68.4% cases caused by antimicrobials, which is higher than those in Spanish cohort (34%)
and LiverTox cohort (45%).[3, 5] Specifically, our cohort includes 28% Amoxicillin-clavulanate and 27%
flucloxacillin cases, which leads to a higher portion of mixed (39%) and cholestatic (26%) cases.
Compared to iDILIC, the LiverTox cohort includes a more even distribution of drugs with 113 drugs that
only occur one time and 148 unique drugs (Supplemental Table 2). Even so, our model was successfully
validated by two independent DILI cohorts, including 385 cases from the Spanish DILI Registry and 191
cases from the LiverTox database.
In addition, rather than reducing statistical power by using a cut point to define chronic cases, we
considered patient time to recovery as a continuous variable. Using a continuous variable has statistical
advantages over those classified by hard threshold (e.g. 6 months). It has been well documented that
there are statistical disadvantages to categorizing continuous variables,[23, 24] which can result in a
considerable loss of statistical power and increase the risk of false positives. Even cut-points based on
medical rationales can be problematic for borderline cases. The accelerated failure time analysis also
allowed us to include cases without complete follow-up information. By contrast, a logistic regression
that compares chronic and acute cases using a six-month cutoff must exclude cases that do not resolve
and have less than six-months of follow-up. In this cohort, only bilirubin was identified as a significant
variable using logistic regression with a six-month cutoff.
We employed the AFT model rather than the Cox proportional hazards in this study. The Cox model is a
semi-parametric model that does not assume that the survival times or outcome must follow a certain
statistical distribution. However, it does rely on the assumption of constant proportional hazard ratios,
and a violation of such will result in an improper fitting of the model and incorrect inferences.[25] We
found that the recovery time data violated the assumptions of the proportional hazards. Alternatively,
the accelerated failure time model does not assume proportional hazards and is easier to interpret but
does require a parametric distribution for the survival times. The AFT multivariate model fit the log-
normal distribution well, except for departures at the tail of the distribution where very few cases
remain.
Total bilirubin at DILI onset was found consistently associated with the length of time to DILI recovery
across drugs in the entire cohort and the drug specific subsets. Previous studies have identified bilirubin
as significantly associated with chronic[3] or persistent[1] DILI but not at DILI onset time; however,
Medina-Caliz et al. did find that bilirubin was significantly elevated in chronic cases in the second month
after onset and that jaundice at onset was a risk factor for DILI chronicity. Other studies define chronic
DILI as six months or one year from onset,[3, 5, 26, 27] whereas our study relied on an accelerated
failure time model rather than a binary cutoff, giving us more statistical power to identify influential
factors (i.e. total bilirubin at onset).
ALP at onset was significant in the entire cohort and in the subgroup that excluded both amoxicillin-
clavulanate and flucloxacillin cases (p=0.026). A similar finding was previously reported in other studies
of DILI chronicity.[1, 3, 27] As in other studies, ALT was not a significant predictor of recovery time. This
is in keeping with the clinical observations that degree of ALT elevation is not predictive of severe clinical
outcomes such as acute liver failure. See reviewer comment and soften ALT.
Injury type was significant in the entire cohort (p=0.001) but not significant in the amoxicillin-
clavulanate and flucloxacillin subgroups. Notably, Both of these drugs have a high prevalence of
cholestatic and mixed cases with 25% and 58% of flucloxacillin cases attributable to cholestatic and
mixed injury, and 33% and 41% of amoxicillin-clavulanate cases attributable to cholestatic and mixed
injury, respectively. Previous studies differ on the significance of injury type with some finding injury
type significant[1, 5] and others finding it not significant.[3] Significance of age was also inconsistent,
with some studies reporting a higher frequency of chronic DILI cases in older patients,[1, 3] while
another reported a higher frequency of younger patients with chronic DILI,[5] and still others reported
no significant association with age.[4, 27] Interestingly, it has been suggested that the prevalence of
certain medications in specific age categories may influence the significance of age in chronic DILI.[1]
Since certain drugs have unique clinical signatures, it is possible the inconsistencies between studies is
due in part to the different drug frequencies and drug properties. In addition, some of these studies
considered elevated liver biochemistries at sixth months as chronic or persistent DILI and others at
twelve months.
Besides clinical factors, drug factors such as lipophilicity, dose, and metabolism can also influence DILI
phenotypes[28] or DILI risk.[14, 29-31] In this study, we found that the extent of hepatic metabolism of
culprit drugs was significantly associated with recovery time. Significant hepatic metabolism has been
linked to hepatocellular injury and severe DILI outcomes.[14] It is not surprising then that our model
performed best when applied to hepatocellular and severe DILI cases (Supplemental Figure 7A and
Supplemental Figure 8, respectively).
We also wanted to determine whether the model could separate cases with the same culprit drug into
different risk categories. Supplemental Figure 9 demonstrates the Kaplan-Meier curve and risk
categories assigned to 79 flucloxacillin cases by the recovery score model. The high and indeterminant
group have a clearly different recovery course, and the log-rank test was slightly significant with a p-
value = 0.032.
A possible limitation of our study is that it is retrospective, and case follow up time is influenced in part
by the clinician decision; cases which are selected as case reports, such as the Spainish DILI cases, may
be followed longer than other cases. Because only five patients were followed for at least twelve
months, extending the model past twelve months is beyond the scope of the model and
See reviewer 3, comment one. Add discussion here.
DILI recovery is determined by liver enzyme data, and very few cases have histological data for
supporting evaluations. Overall statistically, the model works for the entire cohort; however, when
applied to subgroups based on type of liver injury, the model performs best when applied to
hepatocellular cases. This is likely due to mechanistic differences in the development of different kinds
of liver injury. Further study is required to model cholestatic DILI and DILI extending beyond twelve
months. We also noted that two drugs, amoxicillin-clavulanate and flucloxacillin, were the culprit
medication in a large portion (55%) of the cases. In our study, we specifically investigated the
subpopulation taking these two drugs. In addition, this cohort includes very few targeted therapies and
only one tyrosine kinase inhibitor case; thus, the model is not well-trained for the targeted therapies.
Further data including additional targeted therapies would improve performance of the model in this
subpopulation.
In conclusion, we have identified drug related factors and clinical manifestation in the form of degree of
bilirubin and ALP elevation at the onset of DILI that are statistically significantly associated with
prolonged recovery. The model we developed was robust, maintaining significance in drug specific
subgroups, as well as a separate cohort which included a number of different drugs. Considering that
patients with prolonged recovery are associated with persistent symptoms such as itching reducing
quality of life, our recovery score model stratified patients into high/low risk groups for prolonged DILI
recovery, which could inform the plan of follow up in these patients following the initial diagnosis of
DILI. Frequent investigations and clinic visits associated with prolonged recovery may also add to the
cost of care of these patients adding to the burden on health services.
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Female 173 (60%) 40 (23%) 63 (36%) 70 (40%)
Male 117 (40%) 35 (30%) 38 (32%) 44 (38%)
Age (years)
Mean (range) 61 (17 - 91) 65 (32 - 91) 56 (17 - 83) 62 (19 - 85)
Missing (n,%) 1 (0%) 0 (0%) 1 (100%) 0 (0%)
Age-Sex (n,%)
Under 55 Female 71 (24%) 9 (13%) 35 (49%) 27 (38%)
Under 55 Male 30 (10%) 6 (20%) 14 (47%) 10 (33%)
Over 55 Female 101 (35%) 31 (31%) 27 (27%) 43 (43%)
Over 55 Male 88 (30%) 29 (33%) 25 (28%) 34 (39%)
Body Mass Index
Mean (SD) 26.1 (±4.5) 25.4 (±4.2) 26.2 (±4.3) 26.3 (±4.9)
Missing (n,%) 17 (5.9%) 5 (29%) 7 (41%) 5 (29%)
Clinical Presentation (n,%)
Jaundice 69 (24%) 20 (29%) 21 (30%) 28 (41%)
Hospital Admission 200 (69%) 51 (26%) 70 (35%) 79 (40%)
Missing 4 (1%) 1 (25%) 3 (75%) 0 (0.0%)
Hypersensitivity 8 (3%) 1 (12%) 4 (50%) 3 (38%)
Time to Onset (days)
Mean (SD) 42.5 (±80.4) 38.5 (±49.8) 52.4 (±84.8) 36.4 (±91.7)
Median (range) 25 (1 – 955) 29 (4 - 365) 26 (1-519) 22 (1-955)
Follow up (days)
Mean (SD) 82.3 (±73.9) 98.0 (±80.0) 69.2 (±65.2) 83.7 (±75.5)
Median (range) 68 (1-587) 82 (1-543) 53 (3-391) 68 (6-587)
Censored (n, %) 150 (51.7%) 44 (29%) 45 (30%) 61 (41%)
Mean (SD) 85.3 (±91.8) 106.2 (±98.3) 65.9 (±78.3) 84.5 (94.3)
Median (range) 58.5 (1-587) 83 (1 - 543) 39 (3 - 391) 55 (6 -587)
Time to Recovery*
Recovered (n, %) 140 (48.3%) 31 (22%) 56 (40%) 53 (38%)
Mean (SD) 79.2 (±47.9) 86.4 (±40.9) 71.8 (±53.0) 82.7 (±45.9)
Median (range) 73 (10 - 259) 82 (20 - 194) 66 (10 - 231) 76 (11 - 259)
Laboratory Parameters at DILI onset
ALT (/ULN), mean (SD) 12.3 (±11.7) 4.9 (±3.5) 21.0 (±15.5) 9.6 (±4.5)
AST (/ULN), mean (SD) 10.0 (±12.1) 3.6 (±2.7) 16.3 (±15.9) 7.3 (±6.9)
Missing, n (%) 174 (60%) 48 (28%) 55 (32%) 71 (41%)
ALP (/ULN), mean (SD) 2.9 (±2.3) 4.6 (±3.5) 1.6 (±0.9) 3.0 (±1.3)
Bilirubin (/ULN), mean (SD) 5.1 (±4.5) 6.2 (±6.1) 4.4 (±4.2) 5.1 (±3.3)
Severity (n,%)
Mild 42 (14%) 12 (29%) 17 (40%) 13 (31%)
Moderate 244 (84%) 61 (25%) 84 (34%) 99 (41%)
Severe 3 (1%) 1 (33%) 0 (0%) 2 (67%)










Fatal or Transplant removed
Missing 1 (0%) 1 (100%) 0 (0%) 0 (0%)
RUCAM Causality Score (n,%)
Definite or highly probable 111 (38%) 26 (23%) 38 (34%) 47 (42%)
Probable 179 (62%) 49 (27%) 63 (35%) 67 (37%)
Comorbidities (n,%)
Diabetes mellitus 9 (3%) 4 (44%) 3 (33%) 2 (22%)
Hypertension 55 (19%) 19 (35%) 18 (33%) 18 (33%)
Tuberculosis 6 (2%) 0 (0%) 6 (100%) 0 (0%)
Lipid metabolism disorders 5 (2%) 2 (40%) 0 (0%) 3 (60%)
Psoriasis 11 (4%) 4 (36%) 4 (36%) 3 (27%)
Dermatitis 7 (2%) 2 (14%) 1 (14%) 5 (71%)
Missing 24 (8%) 8 (33%) 5 (21%) 11 (46%)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase;
Hypersensitivity: fever, rash, and/or eosinophilia; Severity, Mild: elevated ALT/ALP meeting DILI criteria;
Moderate: elevated ALT/ALP meeting DILI criteria and bilirubin ≥ 2xULN; Severe: elevated ALT/ALP, 
bilirubin ≥ 2xULN, and one of the following: ascites, encephalopathy, international normalization ratio 
>1.5 and/or other organ failure due to DILI; Fatal: death or transplantation due to DILI; RUCAM, Roussel
Uclaf Causality Assessment Method. *Time to recovered includes only cases that resolved within follow-
up time
Table 2. Univariate accelerated failure time estimates of the impact of host factors and drug properties
on the time to biochemical recovery.
Entire Cohort
Time ratio (95% CI)
N=290
Amoxicillin-clavulanate
Time ratio (95% CI)
N=82
Flucloxacillin
Time ratio (95% CI)
N=79
Age 1.00 (1.00-1.01) 1.01 (0.99-1.02) 1.00 (0.99-1.02)
Age below median
(61 years)
0.98 (0.77-1.25) 0.99 (0.73-1.36) 1.00 (0.62-1.62)
Sex (Male) 0.85 (0.67-1.09) 0.82 (0.60-1.10) 0.66 (0.41-1.06)†
Injury Type
Hepatocellular 0.54 (0.40-0.73)*** 0.59 (0.40-0.85)** 0.83 (0.39-1.80)
Mixed 0.79 (0.58-1.06) 0.67 (0.47-0.96)* 0.76 (0.43-1.36)
Severity: Moderate-
severe versus mild
2.09 (1.54-2.83)*** - -
Loge of ALT at onset
(xULN)
0.96 (0.83-1.11) 0.87 (0.71-1.06) 1.02 (0.64-1.62)
Loge of ALP at onset
(xULN)
1.50 (1.25-1.81)*** 1.23 (0.94-1.62) 1.44 (0.80-2.63)
Loge of bilirubin at
onset (xULN)
1.46 (1.31-1.62)*** 1.41 (1.15-1.72)*** 1.44 (1.03-1.99)*
Loge of time to onset
(days)
1.12 (1.00-1.26)† 1.33 (1.13-1.56)*** 0.95 (0.66-1.36)
Drug exposure (days) 1.00 (1.00-1.00) 1.01 (0.97-1.04) 1.03 (0.98-1.09)
Delayed drug
discontinuation
1.02 (0.99-1.05) - -
Extent of metabolism
    ≥ 50% 
0.52 (0.40-0.66)***
Daily Dose 1.00 (1.00-1.00)
Lipophilicity (LogP) 1.00 (0.92-1.08)
Univariate accelerated failure time estimates of the percentage differences in time to biochemical
recovery. Covariates with a time ratio greater than 1 are associated with a prolonged time to recovery.
For example, a time ratio of 0.54 indicates that hepatocellular injury is associated with a 54% decrease
in time to recovery, as compared to cholestatic injury. A time ratio of 1.46 implies that an increase in
bilirubin will increase time to recovery by 46%. Results are shown in the entire cohort and two
subgroups, one comprised of only amoxicillin-clavulanate cases and the other of only flucloxacillin
cases. There was not enough data to estimate severity and delayed drug discontinuation in the
amoxicillin-clavulanate and flucloxacillin cases. Bolded numbers indicate statistical significance.
* p < 0.05; ** p < 0.01; *** p < 0.001, † p < 0.1.
Table 3. Multivariate log‐normal accelerated failure time model for DILI recovery score. β is used as the 
coefficients of the recovery score model.
Covariates β SE TR 95% CI P value
Loge ALP(xULN) at DILI onset 0.227 0.086 1.25 1.06-1.48 0.008
Loge Bilirubin(xULN) at DILI onset 0.277 0.054 1.32 1.19-1.47 <0.001
Loge of Time to Onset (days) 0.161 0.049 1.17 1.07-1.29 0.001
Extent of Metabolism (>50%) -0.440 0.127 0.64 0.50-0.83 <0.001
Number of observations = 290, Number of events = 140, R-squared = 0.219
Likelihood ratio Χ2 test = 72.24 (df = 4, p < 0.0001). Scale= 0.729
TR, Time ratio.





recovery score ≤ 0.44 
(N=53)
High,
recovery score > 1.30
(N=59)
Probability of Recovery (Pr, 95% CI)
3 months 45 (0.37-0.51) 58 (0.38-0.72) 22 (0.08-0.35)
6 months 74 (0.65-0.80) 93 (0.58-0.99) 46 (0.26-0.61)
9 months 85 (0.75-0.91) 93 (0.58-0.99) 54 (0.28-0.70)
Time to Onset
Mean (SD) 43.2 (±80.7) 28.6 (±27.5) 65.2 (±130.9)
Median (range) 25 (1 - 955) 22 (1 - 150) 33 (5 - 955)
Drug-cessation (n, %)
at DILI onset 52 (17.7%) 15 (28.3%) 4 (6.8%)
prior to DILI onset 185 (62.9%) 18 (34.0%) 48 (81.4%)
after DILI onset 57 (19.4%) 20 (37.7%) 7 (11.9%)
Follow up (days)
Mean (SD) 81.8 (±73.6) 50.7 (±43.9) 109.6 (±91.5)
Median (range) 68 (1 - 587) 31 (6 - 181) 86 (6 - 543)
Censored (n, %) 154 (52.4%) 24 (45.3%) 42 (71.2%)
Time to Recovery*
Mean (SD) 79.2 (±47.9) 51.6 (±44.0) 96.6 (±34.0)
Median (range) 73 (10 - 259) 29 (10 - 147) 89 (55 - 190)
Injury Type (n,%)
Cholestatic 77 (26.2%) 10 (18.9%) 28 (47.5%)
Hepatocellular 103 (35.0%) 30 (56.6%) 8 (13.6%)
Mixed 114 (38.8%) 13 (24.5%) 23 (39.0%)
Laboratory Parameters at Onset
ALT (/ULN), mean (SD) 12.8 (±13.6) 12.0 (±18.0) 9.8 (±8.0)
AST (/ULN), mean (SD) 10.0 (±12.1) 7.8 (±6.1) 10.9 (±16.5)
Missing 178 (60.5%) 26 (49.1%) 38 (64.4%)
ALP (/ULN), mean (SD) 2.9 (±2.4) 2.1 (±2.5) 4.3 (±3.3)
Bilirubin (/ULN), mean (SD) 5.2 (±4.7) 1.1 (±1.1) 10.0 (±6.3)
Extent of Metabolism (n,%)
≥ 50 % 85 (29%) 42 (79%) 2 (3%)
< 50 % 209 (71%) 11 (21%) 57 (97%)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase. *Time to
recoverey includes only cases that resolved within follow-up time.
Figure legends
Fig. 1. Inclusion and exclusion criteria. Of the 720 patients in the iDILIC cohort, 386 met inclusion
criteria. These cases included initial and follow-up serum biochemistries and a RUCAM score of six or
more. Cases collected by the Spanish DILI registry were excluded here due to potential conflict with their
inclusion in the Spain validation cohort. After cases with a pre-existing liver disease or multiple causal
drugs were excluded, 294 cases remained.
Fig 2. Kaplan-Meier cumulative event rates for time to recovery in 294 cases. Cases were divided into
high-, indeterminate-, and low-risk groups using the recovery score model. The difference between high-
and low-risk groups was significant according to the log-rank test (p<0.0001).
Fig 3. Kaplan-Meier cumulative event rates for time to recovery in the Spanish DILI registry cohort.
Cases were divided into risk groups using the recovery score model with scores greater than 1.30
assigned to high-risk, scores less than 0.44 assigned to low-risk, and cases between described as
indeterminate. Recovery in the high- and low-risk groups was significantly different according to the log-
rank test (p=0.0025).
Fig 4. Kaplan-Meier cumulative event rates for time to recovery in 191 LiverTox cases. Cases were
divided into risk groups using the recovery score model with scores greater than 1.30 assigned to high-
risk and scores less than 0.44 assigned to low-risk. Indeterminate cases are shown in gray. The
difference between the low- and high-risk groups was significant according to the log-rank test
(p=0.0004).
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